Free tool
FAERS Monitor: Nilstat
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050299 or its brand name (Nilstat, Nystatin). Reports on generic versions are filed under their own applications.
Reports
26,454
Serious
20,553
78% of reports
Hospitalization
11,878
Death reported
3,637
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea2,017
- fatigue1,786
- diarrhoea1,783
- pneumonia1,643
- dyspnoea1,487
- off label use1,475
- vomiting1,390
- drug ineffective1,259
- pain1,225
- death1,152
- pyrexia1,134
- headache1,022
- cough957
- rash944
- acute kidney injury936
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 282 |
| 2005 | 330 |
| 2006 | 365 |
| 2007 | 339 |
| 2008 | 351 |
| 2009 | 434 |
| 2010 | 529 |
| 2011 | 607 |
| 2012 | 748 |
| 2013 | 697 |
| 2014 | 889 |
| 2015 | 1,327 |
| 2016 | 1,672 |
| 2017 | 1,666 |
| 2018 | 2,073 |
| 2019 | 2,196 |
| 2020 | 2,309 |
| 2021 | 1,793 |
| 2022 | 1,654 |
| 2023 | 1,690 |
| 2024 | 1,632 |
| 2025 | 1,651 |
| 2026 | 1,219 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,705 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 936 | 4.9 | 4.6 | 2,893 |
| pneumoniaSignal | 1,643 | 4.1 | 3.9 | 3,811 |
| coughSignal | 957 | 2.7 | 2.6 | 1,049 |
| pyrexiaSignal | 1,134 | 2.6 | 2.5 | 1,141 |
| vomitingSignal | 1,390 | 2.4 | 2.2 | 1,103 |
| diarrhoeaSignal | 1,783 | 2.2 | 2.1 | 1,199 |
| dyspnoeaSignal | 1,487 | 2.1 | 2.0 | 867 |
| nauseaSignal | 2,017 | 2.0 | 1.9 | 1,090 |
| fatigue | 1,786 | 1.8 | 1.7 | 690 |
| rash | 944 | 1.7 | 1.6 | 291 |
| pain | 1,225 | 1.6 | 1.5 | 273 |
| off label use | 1,475 | 1.3 | 1.3 | 132 |
| headache | 1,022 | 1.3 | 1.2 | 71 |
| death | 1,152 | 1.1 | 1.0 | 4 |
| drug ineffective | 1,259 | 0.8 | 0.7 | 102 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.